A myostatin inhibitory antibody combined with insulin, partially rescues the musculoskeletal phenotype of female insulin-deficient diabetic mice
Open Access
- 12 June 2025
- journal article
- endocrinology
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 16, 1558740
Abstract
Introduction: Type 1 diabetes is associated with deficits in both skeletal muscle and bone. Inhibition of myostatin, a negative regulator of muscle mass, was explored as a druggable target to improve the musculoskeletal phenotype associated with insulin-deficient diabetes in female mice.Methods: We investigated whether administration of an inhibitory myostatin antibody (MyoAb) in streptozotocin-induced diabetes in female mice is protective for skeletal muscle and bone. DBA/2J female mice were injected with low-dose streptozotocin or with citrate buffer (vehicle). Subsequently, mice were implanted with insulin-containing or vehicle pellets, with groups being randomized to myostatin or control antibody for 8 weeks. At study end, body composition and in vivo contractile muscle function were assessed, systemic myostatin and glycated hemoglobin were quantified, gastrocnemii were weighed and analyzed for fiber type composition, and femur microarchitecture and biomechanical properties were analyzed.Results: Glycated hemoglobin was significantly higher in diabetic mice compared to non-diabetic mice and diabetic mice treated with insulin. In diabetic mice, the combination of insulin and MyoAb resulted in higher lean mass, higher average gastrocnemius weight and larger muscle fiber size (Type IIB, IIX and hybrid fibers) compared to no treatment. In vivo contractile muscle function testing showed that insulin increased muscle torque in diabetic mice, however there was no effect of the MyoAb. Lastly, microarchitecture analysis of the distal femur showed improvement in some, but not all trabecular bone properties, in mice treated with insulin alone or together with MyoAb. Specifically, trabecular thickness and trabecular bone volume fraction were higher with combination treatment compared to insulin treatment alone.Conclusions: Myostatin inhibition when used in conjunction with insulin treatment improves muscle mass and trabecular bone properties in a mouse model of insulin-deficient diabetes in female mice.Keywords
Funding Information
- National Institute of Diabetes and Digestive and Kidney Diseases
This publication has 57 references indexed in Scilit:
- Pharmacologic Inhibition of Myostatin With a Myostatin Antibody Improves the Skeletal Muscle and Bone Phenotype of Male Insulin‐Deficient Diabetic MiceJBMR Plus, 2023
- Preventing muscle wasting: pro‐insulin C‐peptide prevents loss in muscle mass in streptozotocin‐diabetic ratsJournal of Cachexia, Sarcopenia and Muscle, 2023
- Myostatin serum levels in children with type 1 diabetes mellitusHormones, 2021
- Impact of Genetic and Pharmacologic Inhibition of Myostatin in a Murine Model of Osteogenesis ImperfectaJournal of Bone and Mineral Research, 2020
- Effects of acute aerobic, resistance and combined exercises on 24-h glucose variability and skeletal muscle signalling responses in type 1 diabeticsEuropean Journal of Applied Physiology, 2020
- The effects of alpha-lipoic acid on diabetic myopathyJournal of Endocrinological Investigation, 2017
- Treadmill running induces satellite cell activation in diabetic miceBiochemistry and Biophysics Reports, 2016
- Insulin-like growth factor-1 suppresses the Myostatin signaling pathway during myogenic differentiationBiochemical and Biophysical Research Communications, 2015
- Contemporary Risk of Hip Fracture in Type 1 and Type 2 Diabetes: A National Registry Study From ScotlandJournal of Bone and Mineral Research, 2013
- Myostatin regulates glucose metabolism via the AMP-activated protein kinase pathway in skeletal muscle cellsThe International Journal of Biochemistry & Cell Biology, 2010